Compare Enveric Biosciences Inc (ENVB) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.61. The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | SPHD | |
|---|---|---|
Market Cap | $6.20M | — |
Sector | Health | — |
52-Week High | $17.40 | $53.55 |
52-Week Low | $1.27 | $46.96 |
Enterprise Value | $1.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
SPHD trades at $52.6, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income with a yield around 4.4%. Recent news highlights investor interest in dividend strategies amid market volatility, with articles from Zacks and ETF Trends in August 2026 emphasizing its stability and value appeal.
The outlook for SPHD is positive due to its defensive income strategy in uncertain markets, but risks include interest rate sensitivity and sector concentration. It suits investors seeking steady dividends with lower volatility, though growth may lag during bullish phases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
